The results of the seventh batch of centralized collection are released, how did Qilu "kill the madness"?

The seventh batch of centralized collection, although late, arriv.

"Large centralized procurement" Qilu Pharmaceutical, Yangzijiang Pharmaceutical, Kelun Pharmaceutical, e.

In terms of the number of drug varieties that meet the qualifications for the national procurement application, Qilu Pharmaceutical has the most, with 17, far ahe.

As a major bidder in centralized procurement and the king of consistency evaluation, why does Qilu always become a big winner?

Qilu's seventh batch of collection

Analysis of shortlisted varieties

On July 12, bids will be opened for items with serial numbers 1-30 in the National Centralized Drug Purchasing Catalog.

The news came out, and many varieties of Qilu Pharmaceutical slashed their prices to grab the market, and the decrease in the declared price was basically more than 5

According to the outflow quotations, the declared prices of many varieties of Qilu Pharmaceutical are lower than those of competitors, and it is expected to win another victory in the seventh batch of centralized procureme.

It is reported that Qilu Pharmaceutical has won the bid for products including oseltamivir oral normal-release dosage form, leflunomide tablets, metformin vildagliptin tablets (II), e.

The King of Consistency Evaluation:

Qilu's review performance

As of July 12, 2022, Qilu Pharmaceutical Group has accumulatively reviewed (including deemed approved) 112 drug varieties, and has accumulated 193 approvals (see the end of the article for details), making it a leader among major compani.

In the entire family of Qilu Group, Qilu Pharmaceutical, the headquarters, has carried the banner, Hainan Company is accelerating its efforts, Tianhe Huishi and Anti Pharmaceuticals are doing their be.

Qilu Pharmaceutical is currently the only company with more than 100 reviews of a single pharmaceutical company, with obvious advantag.

Among the over-evaluated varieties, there are 23 varieties with more than 3 approvals, among which, Pramipexole Hydrochloride Sustained-Release Tablets have been over-evaluated for 5, ranking fir.

       Among the 112 drug varieties, 65 are oral solid preparations, 42 are injections, 4 are eye drops, and 1 are spr.

       The number of over-evaluations of injections kept up quickly, basically keeping pace with oral solid preparations, which also reflected that Qilu Pharma had made early preparations and quickly produced injections after the country started the consistency evaluation of injectio.

       The fields involved in the review products include anti-infection, anti-tumor, psychiatry, cardiovascular and cerebrovascular, respiratory system and other fields, and many fields work together, which makes people have to sigh about its strong streng.

       Qilu's continuous review of "ammunition" is their confidence and strength to seize the national mining mark.

       Why Qilu

       Always be the big winner?

       According to Yaozhi data, starting from the "4+7" volume procurement, up to the fifth batch of centralized procurement, Qilu Pharmaceutical Group has selected a total of 34 varieties (36 product specifications), becoming a veritable large centralized procureme.

       Why is Qilu Pharmaceutical always one step ahead in the number of reviews? Can you always be the leader in the number of winning bids in national mining? Let's find out from public da.

       Enterprises that dare to declare consistency evaluation know that they must have a cost advantage in order to gain a firm foothold in subsequent centralized procureme.

       Qilu Pharmaceutical Group has established a number of raw material subsidiaries many years ago, including the establishment of the world's largest production base for raw materials and the most complete cephalosporin products, which can ensure that Qilu may have the advantage of the whole industry cha.

       Therefore, in the first five batches of centralized procurement, almost all of the varieties whose prices have been reduced by more than 90% are Qi.

       ◆ Qilu Pharmaceutical's will to cut prices to compete for the market is very fi.

       Secondly, the most essential requirements for consistency evaluation are quality assurance and equivalent effe.

If the original approval document cut corners, it will be difficult under the new registration requiremen.

       ◆ Qilu has been firm since many years ago: there is no upper limit on research and developme.

       In the changing environment, Qilu, who has been among the top three pharmaceutical companies in the country for many years despite its investment, R&D and technological innovation capabilities, finally tasted the sweetne.

       Opportunities are always given to those who are prepar.

In some small and medium-sized enterprises, they are still thinking about how to be equivale.

Qilu has already sorted out the whole set of materials and submitted the declarati.

       ◆ Finally, Qilu has the courage to bite the bullet, aiming at the varieties that are urgently needed by patients and that are technically difficu.

       Therefore, it has also won a number of "first imitations", and gained a lot in "high imitations" and "difficult imitations", and finally it also showed that it has seized many emerging market segmen.

       Under the background that the product technical threshold has been greatly increased and the price brought by the consistency evaluation and volume procurement, the success rate of product development → product cost advantage → occupying the market → corporate profits and continued high investment in research and development form a positive cyc.

       The scale effect of enterprises will promote the reorganization of the enterprise structure, and a group of internationally competitive enterprises will emerge in the industry, and small enterprises with small scale and low quality in the industry will be gradually eliminat.

       Can Qilu Pharmaceutical go a step further and become a benchmark for Chinese pharmaceutical companies? We will wait and s.